SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?


To: richardred who wrote (2274)7/13/2010 11:26:40 AM
From: Paul Senior  Respond to of 6287
 
I'll add MRX to my watch list.



To: richardred who wrote (2274)7/17/2010 2:46:41 PM
From: richardred  Read Replies (1) | Respond to of 6287
 
Botox-maker Allergan is takeover target?
July 2nd, 2010, 11:35 am · Post a Comment · posted by Colin Stewart

The possible purchase of Allergan is a top topic on this blog’s Facebook page, where all are welcome to visit for news and gossip before it reaches the blog.

Irvine-based Allergan, the manufacturer of wrinkle-fighters Botox and Juvederm, breast implants, eyelash-enhancer Latisse and much more, is a profitable mid-sized company that’s often rumored to be a takeover target.

The latest possible buyer is French pharmaceutical company Sanofi-Aventis SA, which Reuters said is looking to buy an American company — maybe Allergan, but perhaps Biogen, Genzyme, or any of four other companies, according to the Wall Street Journal.

Sanofi-Aventis makes a broad range of drugs, including Plavix, but has little or no presence in the cosmetic-medical market.
inyourface.ocregister.com



To: richardred who wrote (2274)7/17/2010 2:47:23 PM
From: richardred  Read Replies (1) | Respond to of 6287
 
MRX-Oldie
Would-be acquirer Medicis finds itself target of $2.2B Mentor offer.(Medicis Pharmaceutical)(Merry X-Ray acquires SourceOne Healthcare Technologies)(BioVeris in licensing and research agreement with Jewish General Hospital of Montreal)
Medical Device Week
| November 22, 2005 | JOHNSON, HOLLAND | COPYRIGHT 2005 AHC Media LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright
Ads by Google

Would-be acquirer Medicis finds itself target of $2.2B Mentor offer

By HOLLAND JOHNSON

Medical Device Daily Associate Managing Editor

Medicis Pharmaceutical (Scottsdale, Arizona), currently actively seeking to buy breast implant maker Inamed (Santa Barbara, California), found itself over the weekend the target of an acquisition offer by Mentor (Santa Barbara, California).

Mentor's offer to acquire Medicis came less than a week after Medicis was outbid by Allergan (Irvine, California), both companies seeking to acquire Inamed. That competition perhaps emboldened Mentor to make its proposal to acquire Medicis.

In the latest chapter of what is turning into a soap opera whose plot revolves around a scramble to see which company will dominate the lucrative medical aesthetics product market, Mentor proposed a stock-for-stock merger in which Medicis stockholders would receive 0.62 shares of Mentor common stock for each Medicis share.

Based on closing prices on Nov. 18.

accessmylibrary.com



To: richardred who wrote (2274)7/23/2010 1:16:43 PM
From: richardred  Respond to of 6287
 
Things are more clear now for a major product.
Form 8-K for MEDICIS PHARMACEUTICAL CORP

22-Jul-2010

Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement.
On July 22, 2010, Medicis Pharmaceutical Corporation (the "Company") entered into a Settlement Agreement ("Settlement Agreement") and License Agreement ("License Agreement" and, together with the Settlement Agreement, the "Agreements") with Mylan Inc. and certain of its affiliates, including Matrix Laboratories Ltd. and Mylan Pharmaceuticals Inc. (collectively, "Mylan"). Pursuant to the Agreements, the companies agreed to terminate all legal disputes between them relating to SOLODYN? (minocycline HCl, USP) Extended Release Tablets. In addition, Mylan confirmed that the Company's patents relating to SOLODYN? are valid and enforceable, and cover Mylan's activities relating to Mylan's generic SOLODYN? products under Abbreviated New Drug Application ("ANDA") No. 90-911 and ANDA No. 20-1467. Mylan also acknowledged that any prior sales of its generic SOLODYN? products were not authorized by the Company, and agreed to be permanently enjoined from any further distribution of generic SOLODYN? products except pursuant to the License Agreement as described below. The Company agreed to release Mylan from liability arising from any prior sales of its generic SOLODYN? products that were not authorized by the Company.
Under the License Agreement, the Company granted to Mylan a license to make and sell its generic versions of SOLODYN? 45mg, 90mg and 135mg under the SOLODYN? intellectual property rights belonging to the Company commencing in November 2011, or earlier under certain conditions. The Company also granted to Mylan a license to make and sell generic versions of SOLODYN? 65mg and 115mg under the Company's SOLODYN? intellectual property rights upon certain conditions, but not upon any specified date in the future. The License Agreement provides that Mylan will be required to pay the Company royalties based on sales of Mylan's generic SOLODYN? products pursuant to the foregoing licenses.
biz.yahoo.com

IMPAX deal
Message 25220869



To: richardred who wrote (2274)10/18/2010 11:03:48 AM
From: richardred  Respond to of 6287
 
I found it curious that as far as I can tell. MRX was not seeking FDA approval for it's BOTOX copy cat drug DYSPORT for the indication of migraine headaches. AGN just got FDA approval for that indication. Analysts say that could add about 600 mllion dollars to sales.
reuters.com



To: richardred who wrote (2274)12/14/2010 12:52:02 AM
From: richardred  Respond to of 6287
 
UPDATE 2-Galderma bids $967 mln for Swedish implant firm Q-Med


By Helena Soderpalm

STOCKHOLM, Dec 13 (Reuters) - Galderma, a joint venture between L'Oreal (OREP.PA) and Nestle (NESN.VX), launched a bid for Sweden's Q-Med (QMED.ST) for about $970 million, creating a bigger rival in anti-ageing treatments to Botox maker Allergan Inc (AGN.N).

Cosmetic surgery is growing massively across the world with Botox and other facial filler treatments among the most popular procedures. [ID:nN14151304]

Buying Q-Med would give Galderma access to the Swedish firm's Restylane product, an alternative to Botox for smoothing out wrinkles and making faces look plumper and younger.

Q-Med also produces a gel that is used in breast enlargement and body contouring without the need for surgery.

Galderma, which makes products aimed at treating skin, hair and nail diseases like acne, psoriasis and skin cancer, said the offer was worth around 75 crowns per share.

It values Q-Med at 32.9 times earnings per share in the 12 months to end-September. That compares with a price-to-earnings ratio of about 22 times at Allergan, and 12.2 times at U.S. partner Medicis, according to Thomson Reuters data.

Medicis Pharmaceutical Corp (MRX.N) sells Restylane in North America.

"We have called the 10 biggest owners to tell them about the offer and have had a positive reaction," Anders Milton, a director and Chairman of the bid committee at Q-Med said.

Shares in Q-Med, which made a pretax profit of 756 million Swedish crowns on revenues of 1.4 billion in 2009, were up 12.8 percent at 74.75 crowns at 1238 GMT, indicating the market belives that the deal will go through.
reuters.com